Indegene’s share price soared after Axis Direct initiated coverage with a ‘buy’ recommendation, suggesting an 18% upside. The company’s blend of biopharma expertise and AI solutions positions it well for future growth, as per the brokerage firm. Indegene’s share price soared after Axis Direct initiated coverage with a ‘buy’ recommendation, suggesting an 18% upside. The company’s blend of biopharma expertise and AI solutions positions it well for future growth, as per the brokerage firm. Â
